Nuvectis Pharma Stock Current Valuation
| NVCT Stock | USD 5.10 0.20 4.08% |
Valuation analysis of Nuvectis Pharma helps investors to measure Nuvectis Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 116.1 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (5.07) in 2024. Fundamental drivers impacting Nuvectis Pharma's valuation include:
Price Book 8.6137 | Enterprise Value 77.5 M | Enterprise Value Ebitda (7.38) |
Overvalued
Today
Please note that Nuvectis Pharma's price fluctuation is very risky at this time. Calculation of the real value of Nuvectis Pharma is based on 3 months time horizon. Increasing Nuvectis Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Nuvectis Pharma's intrinsic value may or may not be the same as its current market price of 5.10, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.1 | Real 4.7 | Target 20.67 | Hype 4.9 | Naive 2.54 |
The intrinsic value of Nuvectis Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nuvectis Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nuvectis Pharma helps investors to forecast how Nuvectis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nuvectis Pharma more accurately as focusing exclusively on Nuvectis Pharma's fundamentals will not take into account other important factors: Nuvectis Pharma Company Current Valuation Analysis
Nuvectis Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Nuvectis Pharma Current Valuation | 77.5 M |
Most of Nuvectis Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nuvectis Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Nuvectis Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Nuvectis Pharma is extremely important. It helps to project a fair market value of Nuvectis Stock properly, considering its historical fundamentals such as Current Valuation. Since Nuvectis Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nuvectis Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nuvectis Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Nuvectis Current Valuation Historical Pattern
Today, most investors in Nuvectis Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Nuvectis Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Nuvectis Pharma current valuation as a starting point in their analysis.
Nuvectis Pharma Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Nuvectis Pharma has a Current Valuation of 77.5 M. This is 99.46% lower than that of the Biotechnology sector and 98.33% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.53% higher than that of the company.
Nuvectis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nuvectis Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nuvectis Pharma could also be used in its relative valuation, which is a method of valuing Nuvectis Pharma by comparing valuation metrics of similar companies.Nuvectis Pharma is currently under evaluation in current valuation category among its peers.
Nuvectis Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nuvectis Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nuvectis Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Nuvectis Fundamentals
| Return On Equity | -1.4 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | 77.5 M | ||||
| Shares Outstanding | 19.32 M | ||||
| Shares Owned By Insiders | 51.51 % | ||||
| Shares Owned By Institutions | 6.97 % | ||||
| Number Of Shares Shorted | 1.13 M | ||||
| Price To Book | 8.61 X | ||||
| EBITDA | (22.9 M) | ||||
| Net Income | (22.26 M) | ||||
| Cash And Equivalents | 13.57 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 6.98 M | ||||
| Current Ratio | 5.20 X | ||||
| Book Value Per Share | 0.58 X | ||||
| Cash Flow From Operations | (15.95 M) | ||||
| Short Ratio | 7.94 X | ||||
| Earnings Per Share | (1.16) X | ||||
| Target Price | 22.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.4 | ||||
| Market Capitalization | 94.67 M | ||||
| Total Asset | 19.18 M | ||||
| Retained Earnings | (54.24 M) | ||||
| Working Capital | 12.2 M | ||||
| Net Asset | 19.18 M |
About Nuvectis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nuvectis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nuvectis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nuvectis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.